Ongoing Phase 2b Study in Parkinson’s Disease

A Multicenter, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson’s Disease Related Constipation (KARMET).

We are currently conducting a randomized, placebo-controlled trial in up to 150 patients with Parkinson’s Disease (PD). As of March 2021, we have randomized approximately 110 patients. Based on the strength of the existing data, we plan to conduct further studies in patients with PD psychosis and PD dementia. Participating sites include: Scottsdale AZ, Fountain Valley CA, Fresno CA, Pasadena CA, Englewood CO, Washington DC, Atlantis FL, Boca Raton FL, Port Charlotte FL, Sarasota FL, Tampa FL, West Palm Beach FL, Alexandria LA, Cincinnati OH, Cleveland OH, Toledo OH, Lebanon NH, Toms River NJ, Las Vegas NV, Albany NY, New York City NY, Hershey PA, Kirkland WA, and Huntington WV. We would like to thank everyone involved for their support on this important trial.

For further information, please go to ClinicalTrials.gov or contact us at KARMETinfo@enterininc.com.